Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma
Conditions
Interventions
Pomalidomide
Dexamethasone
+1 more
Locations
180
United States
Duplicate_University of Arizona Cancer Center - North Campus /ID# 218407
Tucson, Arizona, United States
VA Central California Health Care System /ID# 200047
Fresno, California, United States
University of California, Los Angeles /ID# 171524
Los Angeles, California, United States
Rocky Mountain Regional VA Medical Center/Eastern Colorado Health Care System /ID# 222904
Aurora, Colorado, United States
Mayo Clinic /ID# 200075
Jacksonville, Florida, United States
Cleveland Clinic Florida /ID# 208884
Weston, Florida, United States
Start Date
October 22, 2018
Primary Completion Date
August 1, 2026
Completion Date
November 1, 2027
Last Updated
June 19, 2025
NCT07249528
NCT06679101
NCT05969860
NCT06057402
NCT06383143
NCT06870760
Lead Sponsor
AbbVie
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions